Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jan 2021

Cheung Irene Y, Cheung Nai-Kong V, Modak Shakeel, Mauguen Audrey, Feng Yi, Basu Ellen, Roberts Stephen S, Ragupathi Govind, Kushner Brian H

Abstract excerpt

PURPOSE: Anti-GD2 monoclonal antibody (mAb) has proven efficacy in high-risk neuroblastoma (HR-NB). A small phase I GD2/GD3 vaccine trial (n = 15) described long-term survival and a favorable safety profile among patients with a history of disease progression (PD). The kinetics of mounting antibody response to vaccine and its prognostic impact on survival are now investigated in a phase II study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to beta-Glucans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Vaccines

Share to Gangliosides

Share to Glioblastoma

Share to Immunogenicity, Vaccine

Share to Lectins, C-Type

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 33326254
DOI: 10.1200/JCO.20.01892
PMCID: PMC8253584

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.PMID 33326254Read ↗

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read ↗

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read ↗

State of the Art in Immunotherapy of NeuroblastomaSemantic proximity Read ↗

GD2-specific Chimeric Antigen Receptor-modified T Cells for the treatment of Refractory and/or Recurrent Neuroblastoma in Pediatric PatientsSemantic proximity Read ↗

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survivalSemantic proximity Read ↗

GD2 targeting CAR T cells for neuroblastomaSemantic proximity Read ↗

Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for NeuroblastomaSemantic proximity Read ↗

High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma ModelSemantic proximity Read ↗

An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersSemantic proximity Read ↗

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastomaSemantic proximity Read ↗

A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastomaSemantic proximity Read ↗

Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in <i>TH-MYCN</i> miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.